J9187 Inj, etoposide, 1 mgInjection, etoposide, 1 mg
J9187 payment limit: $0.094 per 1 MG, effective October 1, 2026 through December 31, 2026, based on 2Q26 ASP data. Coinsurance 20%. Note: Added October 2026.
61269-0410-20 Etopophos, H2 Pharma LLC: 100 billing units per package (1 VIAL, SINGLE-DOSE in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE)16729-0114-08 Etoposide, Accord Healthcare Inc: 500 billing units per package (1 VIAL, MULTI-DOSE in 1 BOX / 25 mL in 1 VIAL, MULTI-DOSE)16729-0114-11 Etoposide, Accord Healthcare Inc: 1000 billing units per package (1 VIAL, MULTI-DOSE in 1 BOX / 50 mL in 1 VIAL, MULTI-DOSE)16729-0114-31 Etoposide, Accord Healthcare Inc: 100 billing units per package (1 VIAL, MULTI-DOSE in 1 BOX / 5 mL in 1 VIAL, MULTI-DOSE)68001-0682-26 Etoposide, Bluepoint Laboratories: 500 billing units per package (1 VIAL, MULTI-DOSE in 1 CARTON / 25 mL in 1 VIAL, MULTI-DOSE)68001-0683-27 Etoposide, Bluepoint Laboratories: 1000 billing units per package (1 VIAL, MULTI-DOSE in 1 CARTON / 50 mL in 1 VIAL, MULTI-DOSE)68001-0265-25 Etoposide, BluePoint Laboratories: 100 billing units per package (1 VIAL, MULTI-DOSE in 1 BOX / 5 mL in 1 VIAL, MULTI-DOSE)68001-0265-26 Etoposide, BluePoint Laboratories: 500 billing units per package (1 VIAL, MULTI-DOSE in 1 BOX / 25 mL in 1 VIAL, MULTI-DOSE)68001-0265-27 Etoposide, BluePoint Laboratories: 1000 billing units per package (1 VIAL, MULTI-DOSE in 1 BOX / 50 mL in 1 VIAL, MULTI-DOSE)63323-0104-05 Etoposide, FreseniUS Kabi USA, LLC: 100 billing units per package (10 BOX in 1 CARTON / 1 VIAL, MULTI-DOSE in 1 BOX / 5 mL in 1 VIAL, MULTI-DOSE)63323-0104-06 Etoposide, FreseniUS Kabi USA, LLC: 100 billing units per package (1 VIAL, MULTI-DOSE in 1 CARTON / 5 mL in 1 VIAL, MULTI-DOSE)63323-0104-25 Etoposide, FreseniUS Kabi USA, LLC: 500 billing units per package (1 VIAL, MULTI-DOSE in 1 CARTON / 25 mL in 1 VIAL, MULTI-DOSE)63323-0104-50 Etoposide, FreseniUS Kabi USA, LLC: 1000 billing units per package (1 VIAL, MULTI-DOSE in 1 CARTON / 50 mL in 1 VIAL, MULTI-DOSE)00143-9376-01 Etoposide, Hikma Pharmaceuticals USA Inc.: 100 billing units per package (1 VIAL in 1 BOX, UNIT-DOSE / 5 mL in 1 VIAL)00143-9510-01 Etoposide, Hikma Pharmaceuticals USA Inc.: 100 billing units per package (1 VIAL in 1 BOX, UNIT-DOSE / 5 mL in 1 VIAL)00143-9511-01 Etoposide, Hikma Pharmaceuticals USA Inc.: 500 billing units per package (1 VIAL in 1 BOX, UNIT-DOSE / 25 mL in 1 VIAL)00143-9512-01 Etoposide, Hikma Pharmaceuticals USA Inc.: 1000 billing units per package (1 VIAL in 1 BOX, UNIT-DOSE / 50 mL in 1 VIAL)71288-0175-05 Etoposide, Meitheal Pharmaceuticals Inc.: 100 billing units per package (1 VIAL, MULTI-DOSE in 1 CARTON / 5 mL in 1 VIAL, MULTI-DOSE)71288-0176-25 Etoposide, Meitheal Pharmaceuticals Inc.: 500 billing units per package (1 VIAL, MULTI-DOSE in 1 CARTON / 25 mL in 1 VIAL, MULTI-DOSE)71288-0177-50 Etoposide, Meitheal Pharmaceuticals Inc.: 1000 billing units per package (1 VIAL, MULTI-DOSE in 1 CARTON / 50 mL in 1 VIAL, MULTI-DOSE)Status E: excluded from the PFS by regulation.
4 of 4 payer prior-auth lists that name J9187 require prior authorization or set conditions: Cigna, HealthSpring.
| Payer | Plan | State | Prior auth | Conditions | Since | Source |
|---|---|---|---|---|---|---|
| Cigna | ACA/IFP | All | prior auth required | May be delegated to eviCore for some clients | Oct 1, 2026 | Master Precertification List (For Health Care Providers) |
| Cigna | Basic Standard | All | prior auth required | May be delegated to eviCore for some clients | Oct 1, 2026 | Master Precertification List (For Health Care Providers) |
| Cigna | Complete/PHS+/Preferred | All | prior auth required | May be delegated to eviCore for some clients | Oct 1, 2026 | Master Precertification List (For Health Care Providers) |
| HealthSpring | Medicare Advantage | All | prior auth required | Oct 1, 2026 | 2026 Q4 Prior Authorization List |
J9187 appears in 16 coverage policies from Aetna, BlueCross BlueShield of South Carolina.
| Payer | Policy | Role in policy | Reviewed | Document |
|---|---|---|---|---|
| Aetna | Hematopoietic Cell Transplantation for Hodgkin's Disease (0495) | listed, no stance (range J9000-J9999) | Jul 2, 2026 | payer document |
| Aetna | Hematopoietic Cell Transplantation for Multiple Myeloma (0497) | listed, no stance (range J9000-J9999) | Aug 5, 2026 | payer document |
| Aetna | Hematopoietic Cell Transplantation for Selected Childhood Solid Tumors (0496) | listed, no stance (range J9000-J9999) | Aug 6, 2026 | payer document |
| Aetna | Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia (0626) | listed, no stance (range J9000-J9999) | Sep 18, 2026 | payer document |
| Aetna | Infusion Pumps (0161) | covered if criteria are met (range J9000-J9999) | Mar 31, 2026 | payer document |
| Aetna | Injectable Medications (0020) | listed, no stance (range J9000-J9999) | Mar 5, 2026 | payer document |
| Aetna | Margetuximab-cmkb (Margenza) (0985) | listed, no stance (range J9000-J9999) | May 27, 2026 | payer document |
| Aetna | Negative Pressure Wound Therapy (0334) | listed, no stance (range J9000-J9999) | Jun 8, 2026 | payer document |
| Aetna | Pertuzumab Products (0973) | listed, no stance (range J9000-J9999) | Apr 27, 2026 | payer document |
| Aetna | Phototherapy and Photochemotherapy (PUVA) for Skin Conditions (0205) | listed, no stance (range J9000-J9999) | May 18, 2026 | payer document |
| Aetna | Revakinagene Taroretcel-lwey (Encelto) (1079) | listed, no stance (range J8501-J9999) | Oct 5, 2026 | payer document |
| Aetna | Tumor Chemoresistance Assays (0758) | listed, no stance (range J9000-J9999) | Dec 2, 2025 | payer document |
| Aetna | Tumor Chemosensitivity Assays (0245) | listed, no stance (range J9000-J9999) | Apr 13, 2026 | payer document |
| BlueCross BlueShield of South Carolina | Hematopoietic Cell Transplantation for Breast Cancer (CAM 80127) | listed, no stance (range J9000-J9999) | Jul 1, 2026 | payer document |
| BlueCross BlueShield of South Carolina | Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults (CAM 80124) | unproven / investigational (range J9000-J9999) | Jul 1, 2026 | payer document |
| BlueCross BlueShield of South Carolina | Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome (CAM 80117) | listed, no stance (range J9000-J9999) | Jan 1, 2026 | payer document |
From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.